Vcanbio Cell & Gene Engineering Corp., Ltd (SHA:600645)
China · Delayed Price · Currency is CNY 17.78
-0.24 (-1.33%)
Sep 11, 2026, 3:00 PM CST
SHA:600645 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 8,106 | 11,489 | 8,799 | 9,485 | 7,960 | 11,811 | |
Market Cap Growth | -28.48% | 30.57% | -7.24% | 19.16% | -32.61% | 28.71% |
Enterprise Value | 6,400 | 9,948 | 7,548 | 8,212 | 6,852 | 10,829 |
Last Close Price | 17.78 | 25.20 | 19.30 | 20.27 | 17.01 | 25.24 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 71.04 | 100.93 | 87.68 | 89.10 | 70.45 | 76.04 |
Forward PE | - | 72.92 | 56.77 | 48.99 | 48.99 | 48.99 |
PS Ratio | 5.80 | 7.90 | 5.55 | 5.97 | 5.12 | 7.69 |
PB Ratio | 2.14 | 3.06 | 2.40 | 2.50 | 2.18 | 3.34 |
P/TBV Ratio | 2.77 | 3.94 | 3.15 | 3.29 | 2.90 | 4.50 |
P/FCF Ratio | 29.12 | 43.51 | 40.39 | 45.08 | 48.92 | 61.13 |
P/OCF Ratio | 25.08 | 36.63 | 30.85 | 31.72 | 30.39 | 36.80 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 4.58 | 6.84 | 4.76 | 5.17 | 4.41 | 7.05 |
EV/EBITDA Ratio | 22.14 | 39.75 | 24.73 | 29.15 | 27.01 | 47.63 |
EV/EBIT Ratio | 42.10 | 64.94 | 46.25 | 59.45 | 47.94 | 87.02 |
EV/FCF Ratio | 22.99 | 37.67 | 34.64 | 39.03 | 42.12 | 56.04 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.02 | 0.02 | 0.03 | 0.03 | 0.04 | 0.02 |
Debt / EBITDA Ratio | 0.23 | 0.28 | 0.41 | 0.45 | 0.50 | 0.33 |
Debt / FCF Ratio | 0.25 | 0.30 | 0.57 | 0.61 | 0.87 | 0.43 |
Net Debt / Equity Ratio | -0.46 | -0.44 | -0.38 | -0.38 | -0.34 | -0.31 |
Net Debt / EBITDA Ratio | -6.13 | -6.56 | -4.60 | -5.16 | -4.93 | -4.90 |
Net Debt / FCF Ratio | -6.28 | -6.22 | -6.44 | -6.91 | -7.70 | -5.76 |
Asset Turnover | 0.27 | 0.28 | 0.30 | 0.30 | 0.30 | 0.31 |
Inventory Turnover | 1.77 | 1.98 | 2.07 | 2.04 | 2.15 | 2.11 |
Quick Ratio | 1.69 | 1.61 | 1.46 | 1.49 | 1.36 | 1.24 |
Current Ratio | 1.91 | 1.82 | 1.65 | 1.69 | 1.57 | 1.46 |
Return on Equity (ROE) | 2.95% | 2.79% | 2.40% | 2.65% | 2.97% | 4.30% |
Return on Assets (ROA) | 1.99% | 1.82% | 1.91% | 1.61% | 1.73% | 1.57% |
Return on Invested Capital (ROIC) | 4.78% | 4.16% | 4.66% | 4.33% | 4.08% | 3.43% |
Return on Capital Employed (ROCE) | 4.40% | 4.00% | 4.30% | 3.50% | 3.70% | 3.40% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 1.44% | 0.99% | 1.14% | 1.12% | 1.42% | 1.31% |
FCF Yield | 3.43% | 2.30% | 2.48% | 2.22% | 2.04% | 1.64% |
Payout Ratio | - | - | - | - | - | 1.03% |
Buyback Yield / Dilution | -5.93% | 0.18% | 1.45% | 1.69% | -0.02% | -0.17% |